ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1037

Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

Alice Terrett1, Athena Chin2, Mihye Kwon3, Samuel Whittle4 and Catherine Hill5, 1The Queen Elizabeth Hospital, Adelaide, Australia, 2Royal Adelaide Hospital, Tranmere, South Australia, Australia, 3Konyang University, College of Medicine, Daejeon, Republic of Korea, 4The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 5The Queen Elizabeth Hospital, Woodville, South Australia, Australia

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis, surgery, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional outcomes. However, large joint replacements remain relatively common in this population (Nikiphorou et al 2014) and concerns remain regarding the optimal method for balancing the risks and benefits of the use of DMARDs in the perioperative period. The aim of this review is to compare existing clinical practice guideline recommendations for the perioperative management of DMARDs in patients with rheumatic diseases.

Methods: A scoping review was performed. We searched Medline and EMBASE and performed a hand search of references to identify guidelines published since 2014 by national or international academic societies in rheumatology that addressed perioperative management of DMARDs in any of adult RA, Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), juvenile idiopathic arthritis (JIA) or systemic lupus erythematosus (SLE). Target drugs were csDMARDs (methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, minocycline), bDMARDs (adalimumab, etanercept, infliximab, golimumab, certolizumab, abatacept, tocilizumab, rituximab, sarilumab, anakinra), tsDMARDs (tofacitinib, baricitinib, upadacitinib, filgotinib). In the case of multiple versions of the same guideline, only the most recent guideline was included. Data extraction was performed in duplicate by two authors.

Results: We included 12 guidelines (5 European, 1 North American, 1 South American, 5 Asia-Pacific; publication year range 2014-2024). 2 (17%) were a standalone guideline for the use of DMARDs in the perioperative period; the remaining 10 (83%) incorporated a recommendation within a broader guideline. RA was the sole rheumatic condition covered in 7 (58%) guidelines. Recommendations for csDMARDs were included in 8 (67%), bDMARDs in 8 (67%) and tsDMARDs in 5 (42%). Overall, low to moderate quality evidence supported these recommendations and most were based on evidence from studies of participants undergoing elective orthopaedic surgery. Guidelines varied in development process, format, the choice of evidence system, level of evidence, and strength of recommendation. Similar themes for recommendations for bDMARDs and tsDMARDs were observed, however variations in the recommendations for csDMARDs were noted between guidelines.  

Conclusion: Although guidelines for the use of DMARDs in the perioperative period are widely available, the development process and the presentation of recommendations varies between guidelines. There is a lack of high quality evidence to support recommendations for non-elective, non-orthopaedic surgery cases. Variations in recommendations were more common for csDMARDs compared to b/tsDMARDs, potentially leading to more practice variation in csDMARD use in the perioperative period.  

Nikiphorou E, Carpenter L, Morris S, et al. Hand and Foot Surgery Rates in Rheumatoid Arthritis Have Declined From 1986 to 2011, but Large‐Joint Replacement Rates Remain Unchanged: Results From Two UK Inception Cohorts. Arthritis & Rheumatology. 2014 May;66(5):1081–9.


Disclosures: A. Terrett: None; A. Chin: None; M. Kwon: None; S. Whittle: None; C. Hill: Vifor Pharmaceuticals, 5.

To cite this abstract in AMA style:

Terrett A, Chin A, Kwon M, Whittle S, Hill C. Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/recommendations-for-the-perioperative-use-of-dmards-in-rheumatic-diseases-a-scoping-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/recommendations-for-the-perioperative-use-of-dmards-in-rheumatic-diseases-a-scoping-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology